NUS
Nu Skin Enterprises, Inc.Price & Indicators
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Dividend Payments | $2.9M | Q1 2026 | — |
|
|
|||
| EPS excluding certain charges non-GAAP | $0.14 | Q1 2026 | — |
| Stock Repurchases Remaining Authorization | $137.3M | Q1 2026 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Household & Personal Products — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NUS
this stock
Nu Skin Enterprises, Inc.
|
$246.64M | -46.8% | +11.9% | 4.7 | 7.4% |
|
PG
PROCTER & GAMBLE Co
|
$355.69B | +7.3% | +0.3% | 22.3 | 1.1% |
|
UL
Unilever PLC
|
$135.09B | -2.4% | — | — | 0.1% |
|
CL
Colgate Palmolive Co
|
$74.45B | +18.5% | +1.7% | 36.1 | 2.6% |
|
KMB
Kimberly Clark Corp
|
$38.09B | +15.1% | -15.0% | 18.0 | 13.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NUS | -3.8% | -4.5% | -51.9% | -3.8% | -46.8% |
| SPY | +0.9% | +1.4% | +7.6% | +0.1% | +9.7% |
| vs SPY | -4.7% | -5.9% | -59.4% | -3.9% | -56.5% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.